Brought to you by 
Acologix gets N. American, European rights to Toray's TRK-820
20 Oct 2006
Executive Summary
Toray Industries has granted Acologix (focused on the development of therapeutics for bone and kidney diseases) an exclusive North American development and marketing license to TRK-820. The companies will co-develop the drug candidate in Europe, with Acologix getting the option to market it there.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acologix gets N. American, European rights to Toray's TRK-820
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice